S. 1302: Increasing Transparency in Generic Drug Applications Act

S. 1302 is a federal bill in the 119th Congress. Before this bill, generic drug makers submitting applications to the Food and Drug Administration often found out their proposed medication did not match the inactive ingredients of the brand-name reference drug, but regulators were not required to specify… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.